Sana Biotechnology (SANA) shares more than doubled in recent Wednesday trading, a day after the company reported positive initial results from a study involving its hypoimmune technology in type 1 diabetes treatment.
On Wednesday, TD Cowen upgraded its rating on the stock to buy from hold.
Intraday volume in Sana topped 88.3 million shares Wednesday versus the daily average of 2.01 million shares.
Sana said late Tuesday the study showed that its hypoimmune technology enabled the transplanted islet cells to avoid rejection and produce insulin without immunosuppression.
Price: 4.21, Change: +2.56, Percent Change: +155.15
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。